Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
05
06
2020
revised:
16
09
2020
accepted:
30
11
2020
pubmed:
30
12
2020
medline:
25
2
2022
entrez:
29
12
2020
Statut:
ppublish
Résumé
PAOLA1 is a phase III study assessing olaparib maintenance therapy in advanced high-grade ovarian carcinoma patients responding to first-line platinum-taxane-based chemotherapy plus bevacizumab as standard of care. Randomization was stratified by treatment outcome and tumor BRCA1/2 status (tBRCA) at screening. tBRCA was tested on formalin-fixed, paraffin-embedded tumor blocks on 5 French platforms using 2 next-generation sequencing methods based either on hybrid capture or amplicon technology. One of the exploratory objectives was to assess the concordance between germline (gBRCA) and tBRCA testing in French patients. gBRCA testing was performed on blood samples on the same platforms. From May 2015 to July 2017, tBRCA tests were performed for 1176 screened patients. Only 52 (4.4%) tumor samples were noncontributive. The median interval between reception of the tumor sample and availability of the tBRCA status result was 37 days (range = 8-260). A pathogenic variant was reported in 27.1% tumor samples (319 of 1176 screened patients). tBRCA and gBRCA testing were performed for 451 French patients with negative results for both tests in 306 patients (67.8%) and positive results for both tests in 85 patients (18.8%). Only 1 large genomic rearrangement of BRCA1 was detected, exclusively in the blood sample. Interestingly, tBRCA testing revealed 6.4% of pathogenic variant (29 of 451) not detected by gBRCA testing. tBRCA testing is an appropriate tool with an acceptable turnaround time for clinical practice and a low failure rate, ensuring reliable identification of patients likely to benefit from poly(ADP-ribose) polymerase inhibitor therapy.
Sections du résumé
BACKGROUND
PAOLA1 is a phase III study assessing olaparib maintenance therapy in advanced high-grade ovarian carcinoma patients responding to first-line platinum-taxane-based chemotherapy plus bevacizumab as standard of care. Randomization was stratified by treatment outcome and tumor BRCA1/2 status (tBRCA) at screening.
METHODS
tBRCA was tested on formalin-fixed, paraffin-embedded tumor blocks on 5 French platforms using 2 next-generation sequencing methods based either on hybrid capture or amplicon technology. One of the exploratory objectives was to assess the concordance between germline (gBRCA) and tBRCA testing in French patients. gBRCA testing was performed on blood samples on the same platforms.
RESULTS
From May 2015 to July 2017, tBRCA tests were performed for 1176 screened patients. Only 52 (4.4%) tumor samples were noncontributive. The median interval between reception of the tumor sample and availability of the tBRCA status result was 37 days (range = 8-260). A pathogenic variant was reported in 27.1% tumor samples (319 of 1176 screened patients). tBRCA and gBRCA testing were performed for 451 French patients with negative results for both tests in 306 patients (67.8%) and positive results for both tests in 85 patients (18.8%). Only 1 large genomic rearrangement of BRCA1 was detected, exclusively in the blood sample. Interestingly, tBRCA testing revealed 6.4% of pathogenic variant (29 of 451) not detected by gBRCA testing.
CONCLUSIONS
tBRCA testing is an appropriate tool with an acceptable turnaround time for clinical practice and a low failure rate, ensuring reliable identification of patients likely to benefit from poly(ADP-ribose) polymerase inhibitor therapy.
Identifiants
pubmed: 33372675
pii: 6054797
doi: 10.1093/jnci/djaa193
pmc: PMC8246800
doi:
Substances chimiques
BRCA1 Protein
0
BRCA2 Protein
0
Phthalazines
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
917-923Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Ann Oncol. 2018 May 1;29(5):1203-1210
pubmed: 29635390
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Gynecol Oncol. 2020 Mar;156(3):517-522
pubmed: 31883735
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
J Natl Cancer Inst. 2020 Feb 1;112(2):161-169
pubmed: 31076742
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Semin Oncol. 2017 Jun;44(3):187-197
pubmed: 29248130
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Cancer. 2012 Nov 1;118(21):5210-6
pubmed: 22544547
Ann Oncol. 2018 Jun 1;29(6):1366-1376
pubmed: 29750420
Drug Des Devel Ther. 2018 May 29;12:1501-1509
pubmed: 29881257
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Oncotarget. 2018 Apr 13;9(28):19463-19468
pubmed: 29731958
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483